The Institute of Medicine (IOM) has acknowledged that there is individual susceptibility to vaccine reactions for genetic, biological and environmental reasons, but that vaccine providers cannot accurately predict prior to a vaccine’s administration who will suffer complications, injury or death from vaccination.1 However, a person who has previously had a serious reaction to a vaccination or is acutely or chronically ill should become informed about all potential risks associated with vaccination and discuss any concerns with a trusted health care professional before receiving a poliovirus vaccine or any other vaccine.
The poliovirus vaccine is commonly administered in a combination vaccine which includes the diphtheria, tetanus, and acellular pertussis vaccine (DTaP), hepatitis B and Haemophilus influenzae type b (Hib) vaccines. It is important to review the manufacturer product insert prior to receiving a combination vaccine that contains the poliovirus vaccine.
Pediarix (Diphtheria and tetanus toxoids and acellular pertussis, hepatitis B recombinant and inactivated poliovirus vaccine manufactured by GlaxoSmithKline.)
Kinrix (Diphtheria and tetanus toxoids, acellular pertussis and inactivated poliovirus vaccine manufactured by GlaxoSmithKline.)
Quadracel (Diphtheria and tetanus toxoid, acellular pertussis and inactivated poliovirus vaccine manufactured by Sanofi Pasteur.)
Pentacel (Diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus and Haemophilus b conjugate (tetanus toxoid conjugate) vaccine manufactured by Sanofi Pasteur.)
VAXELIS (Diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus b conjugate, and hepatitis B recombinant vaccine manufactured by MCM Vaccine Company.)
IPOL (inactive poliovirus (Monkey Kidney Cell) manufactured by Sanofi Pasteur)
In 1994, the Institute of Medicine (IOM) reported that there was compelling scientific evidence to establish a causal relationship between the oral poliovirus vaccine (OPV) and paralytic and non-paralytic polio. The committee also affirmed that OPV could cause vaccine-strain polio in the contacts of vaccinated individuals. Additionally, the IOM committee also favored acceptance of an association between OPV and Guillain-Barré Syndrome (GBS). An immune-mediated painful and disabling neurological disorder that can occur after viral infection or vaccination, GBS involves inflammation of the peripheral nervous system and can cause temporary or permanent paralysis that may lead to death. The committee, however, reported that there was insufficient evidence to accept or reject a causal relationship between the inactivated, injectable poliovirus vaccine (IPV) and GBS. A potential association between poliovirus vaccines, both OPV and IPV, and transverse myelitis, a rare neurological condition which causes spinal inflammation, was also evaluated in this report. Committee members reported that the evidence was insufficient to accept or reject a causal relationship between OPV and transverse myelitis and that there was no evidence to determine a relationship between IPV and this serious neurological condition.2
Vaccine-associated paralytic polio (VAPP) was associated with OPV immediately following the vaccine’s introduction. When OPV was in use in the U.S., VAPP was estimated to occur at a rate of one case per 2.4 million doses, or one case per 750,000 doses, if OPV was administered as the first dose. On June 17, 1999, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to stop the use of OPV in the U.S., by January of 2000.3 OPV, however, remains in use globally, and is the vaccine primarily used in global campaigns that are focused on eradicating polio.4
In addition to VAPP, OPV can also cause vaccine-derived poliovirus (VDPV). OPV is a live virus vaccine and individuals who receive the vaccine will shed vaccine-strain poliovirus in the stool for several weeks following vaccination. In areas with poor sanitation, the vaccine-strain virus can spread within a community for an extended period. When this occurs, the vaccine-strain polio virus will undergo genetic changes and, in some cases, transform into circulating VDPV (cVDPV) and cause paralysis. Public health officials report that cVDPV occurs in under-vaccinated communities or due to poorly administered vaccination programs.5
In 2019, the majority of reported paralytic polio cases were caused by outbreaks of type 2 cVDPV (cVDPV2) which were reported in Niger, Nigeria, Cameroon, Benin, Ghana, Ethiopia, Somalia, China, Myanmar, Kenya, Central African Republic (CAR), Angola, Papua New Guinea, and Indonesia.6
The U.S. government recognizes the following as OPV vaccine injuries:7
The U.S. government recognizes the following as IPV vaccine injuries:8
As of January 2, 2026, there have been 24,976 adverse events reported following OPV including 1,067 deaths (nearly 90 percent in children under age six). There have also been 90,449 reports of adverse events associated with IPV containing vaccines including 2,190 deaths. However, the number of vaccine-related injuries and deaths reported to VAERS may not reflect the true number of serious health problems that occur after polio vaccination.
Even though the National Childhood Vaccine Injury Act of 1986 legally required pediatricians and other vaccine providers to report serious health problems following vaccination to federal health agencies (VAERS), many doctors and other medical workers giving vaccines to children and adults fail to report vaccine-related health problems to VAERS. There is evidence that only between one and 10 percent of serious health problems that occur after use of prescription drugs or vaccines in the U.S. are ever reported to federal health officials, who are responsible for regulating the safety of drugs and vaccines and issue national vaccine policy recommendations.910111213
As of December 1, 2025, there have been 310 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following OPV containing vaccines, including 28 deaths and 282 serious injuries. There have been 531 claims for injuries and deaths following IPV containing vaccines, including 79 deaths and 452 serious injuries. Of that number, the U.S. Court of Claims administering the VICP has compensated 251 children and adults, who have filed claims for polio vaccine associated injury and death.14
In 1960, Dr. Bernice Eddy discovered that the rhesus monkey kidney cells used to make the first injectable poliovirus vaccine, and the first experimental oral polio vaccines, could cause cancer when injected into lab animals. Later that year, the cancer-causing virus in the rhesus monkey kidney cells was identified as simian virus 40 (SV40), the 40th monkey virus to be discovered. Public health officials, who were aware of the virus and its potential to cause cancer, chose not to make this information public. Further, they allowed the contaminated vaccine to be injected into millions of Americans between 1955 and 1963.15
The U.S. government and vaccine manufacturers have reported that all SV40 tainted poliovirus vaccines were removed from the market by 1963; however, there is evidence that SV40 was still present in the OPV and administered to children from 1963 through the 1990’s.161718
In 2002, the Institute of Medicine (IOM) concluded that the biological evidence is strong that SV40 is a transforming virus
and that the biological evidence is of moderate strength that SV40 exposure could lead to cancer in humans under natural conditions.
It also concluded that the evidence is inadequate to accept or reject a causal relationship between SV40-containing polio vaccines and cancer.
19 SV40-associated cancers include brain cancers, bone cancers, malignant mesothelioma, and non-Hodgkin’s lymphoma.2021
The 2002 IOM committee recommended that additional research be completed to determine whether a causal relationship exists between SV40 and cancer, but they have not published any further reports on this subject. U.S. public health officials have acknowledged that live SV40 contaminated both inactivated and live polio vaccines between 1955 and 1963, but they continue to deny that SV40 causes cancer in humans.22
IMPORTANT NOTE: NVIC encourages you to become fully informed about Polio and the Polio vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.